These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38993030)

  • 1. Clinical trial: The effectiveness of long-acting somatostatin analogue for output reduction of high-output intestinal fistula or small bowel enterostomy. A randomised controlled trial.
    Timmer AS; de Vries F; Gans SL; Zwanenburg PR; Bemelman WA; Dijkgraaf MGW; Dijkstra G; van der Heide F; Haveman JW; Serlie MJ; Boermeester MA
    Aliment Pharmacol Ther; 2024 Sep; 60(6):727-736. PubMed ID: 38993030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review: pharmacotherapy for high-output enterostomies or enteral fistulas.
    de Vries FEE; Reeskamp LF; van Ruler O; van Arum I; Kuin W; Dijksta G; Haveman JW; Boermeester MA; Serlie MJ
    Aliment Pharmacol Ther; 2017 Aug; 46(3):266-273. PubMed ID: 28613003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis.
    Goltstein LCMJ; Grooteman KV; Rocco A; Holleran G; Frago S; Salgueiro PS; Aparicio T; Scaglione G; Chetcuti Zammit S; Prados-Manzano R; Benamouzig R; Nardone G; McNamara D; Benallaoua M; Michopoulos S; Sidhu R; Kievit W; Drenth JPH; van Geenen EJM
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):922-932. PubMed ID: 34508668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, placebo-controlled, double-blind study of the efficacy of lanreotide 30 mg PR in the treatment of pancreatic and enterocutaneous fistulae.
    Gayral F; Campion JP; Regimbeau JM; Blumberg J; Maisonobe P; Topart P; Wind P;
    Ann Surg; 2009 Dec; 250(6):872-7. PubMed ID: 19953707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blind evaluation of the effect of octreotide (SMS 201-995), a somatostatin analogue, on small-bowel fistula output.
    Nubiola-Calonge P; Badía JM; Sancho J; Gil MJ; Segura M; Sitges-Serra A
    Lancet; 1987 Sep; 2(8560):672-4. PubMed ID: 2887951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chyme Reinfusion for Small Bowel Double Enterostomies and Enteroatmospheric Fistulas in Adult Patients: A Systematic Review.
    Bhat S; Sharma P; Cameron NR; Bissett IP; O'Grady G
    Nutr Clin Pract; 2020 Apr; 35(2):254-264. PubMed ID: 31549468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of somatostatin analogues in the management of enterocutaneous fistulae.
    Jamil M; Ahmed U; Sobia H
    J Coll Physicians Surg Pak; 2004 Apr; 14(4):237-40. PubMed ID: 15228830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
    Meijer E; Drenth JP; d'Agnolo H; Casteleijn NF; de Fijter JW; Gevers TJ; Kappert P; Peters DJ; Salih M; Soonawala D; Spithoven EM; Torres VE; Visser FW; Wetzels JF; Zietse R; Gansevoort RT;
    Am J Kidney Dis; 2014 Mar; 63(3):446-55. PubMed ID: 24342522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chyme Reinfusion in Intestinal Failure Related to Temporary Double Enterostomies and Enteroatmospheric Fistulas.
    Picot D; Layec S; Seynhaeve E; Dussaulx L; Trivin F; Carsin-Mahe M
    Nutrients; 2020 May; 12(5):. PubMed ID: 32403450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial.
    Naimi RM; Hvistendahl M; Enevoldsen LH; Madsen JL; Fuglsang S; Poulsen SS; Kissow H; Pedersen J; Nerup N; Ambrus R; Achiam MP; Svendsen LB; Holst JJ; Hartmann B; Hansen SH; Dragsted LO; Steensberg A; Mouritzen U; Hansen MB; Jeppesen PB
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):354-363. PubMed ID: 30880176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review and meta-analysis of the role of somatostatin and its analogues in the treatment of enterocutaneous fistula.
    Stevens P; Foulkes RE; Hartford-Beynon JS; Delicata RJ
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):912-22. PubMed ID: 21814141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin analogues for the treatment of enterocutaneous fistulas: a systematic review and meta-analysis.
    Coughlin S; Roth L; Lurati G; Faulhaber M
    World J Surg; 2012 May; 36(5):1016-1029. PubMed ID: 22419412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease.
    Temmerman F; Ho TA; Vanslembrouck R; Coudyzer W; Billen J; Dobbels F; van Pelt J; Bammens B; Pirson Y; Nevens F
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2353-9.e1. PubMed ID: 26073493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).
    An Z; Lei T; Duan L; Hu P; Gou Z; Zhang L; Durand-Gasselin L; Wang N; Wang Y; Gu F;
    BMC Endocr Disord; 2020 May; 20(1):57. PubMed ID: 32366244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous irrigation and suction with a triple-cavity drainage tube in combination with sequential somatostatin-somatotropin administration for the management of postoperative high-output enterocutaneous fistulas: Three case reports and literature review.
    Kong X; Cao Y; Yang D; Zhang X
    Medicine (Baltimore); 2019 Nov; 98(46):e18010. PubMed ID: 31725672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin versus octreotide in the treatment of patients with gastrointestinal and pancreatic fistulas.
    Leandros E; Antonakis PT; Albanopoulos K; Dervenis C; Konstadoulakis MM
    Can J Gastroenterol; 2004 May; 18(5):303-6. PubMed ID: 15152279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of somatostatin analogue for intestinal and pancreatic fistulas].
    Paran H; Neufeld D; Epstein T; Bendahan J; Freund U
    Harefuah; 1991 Feb; 120(4):185-6. PubMed ID: 2066018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucous fistula refeeding in premature neonates with enterostomies.
    Wong KK; Lan LC; Lin SC; Chan AW; Tam PK
    J Pediatr Gastroenterol Nutr; 2004 Jul; 39(1):43-5. PubMed ID: 15187779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of mucous fistula refeeding in preterm infants: an exploratory randomized controlled trial.
    Lee ES; Kim EK; Shin SH; Jung YH; Song IG; Kim YJ; Kim HY; Choi YH; Moon KC; Kim B
    BMC Pediatr; 2023 Mar; 23(1):137. PubMed ID: 36991415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.